Nature Reviews:一文+一图读懂Akk菌——下一代益生菌中的新星
创作:圆圈儿 审核:mildbreeze 07月01日
  • 小鼠模型和人群研究中,Akk菌丰度降低与多种疾病有关;
  • Akk菌可改善小鼠代谢紊乱(如肥胖、糖尿病、脂肪肝)、神经退行性疾病、肠道炎症和癌症(结肠癌和免疫治疗反应);
  • 巴氏灭活的Akk菌比活菌更有效,小鼠和人体概念验证研究证明了其安全性和有效性;
  • Akk菌通过其特定代谢物或膜蛋白作用于宿主细胞或受体,促进维持肠屏障,调控宿主免疫并抑制炎症;
  • 与其他下一代益生菌相比,Akk菌对宿主底物具有代谢偏好且灭活后仍有效。
#一张图读懂系列文献#
主编推荐语
mildbreeze
嗜黏蛋白阿克曼菌(俗称Akk菌)是一种肠道共生菌,也是下一代益生菌中的“潜力股”,在转化应用研究方面走在了前列。Nature Reviews Gastroenterology and Hepatology最新发表了由比利时天主教鲁汶大学Patrice Cani教授主笔的综述文章,回顾了Akk菌的研究历史,重点介绍了其在健康和疾病中的作用和机制,认为改善肠屏障可能是Akk菌诸多健康功效的基础核心,并将Akk菌与其他有代表性的下一代益生菌进行了比较。为了让读者能更直观地了解这个菌的研究进展,我们特别将文中的图片编译为一图读懂,希望能帮你长知识。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms

嗜黏蛋白阿克曼菌:下一代有益微生物的范例

10.1038/s41575-022-00631-9

05-31, Review

Abstract & Authors:展开

Abstract:收起
Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of studies moving from correlations to causality. The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial. In this Review, we cover the history of the discovery of A. muciniphila and summarize the numerous findings and main mechanisms of action by which this intestinal symbiont improves health. A comparison of this microorganism with other next-generation beneficial microorganisms that are being developed is also made.

First Authors:
Patrice D Cani

Correspondence Authors:
Patrice D Cani

All Authors:
Patrice D Cani,Clara Depommier,Muriel Derrien,Amandine Everard,Willem M De Vos

评论